Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca’s Business Development Head Grady Outlines Strategy Mix

Executive Summary

AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.


Related Content

2016 Pharma Dealmaking: Waiting On The High-Value Deals
AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D
UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
AstraZeneca Hands LEO Dermatology Potential
Aspen Acquires AstraZeneca Anesthetics Portfolio Ex-US
AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes
AstraZeneca Offloads Two Mature CV Drugs For $500m
AstraZeneca Ups Betting Ante On Moderna's Messenger RNA Technology


Related Companies